<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: A brief exposure to systemic <z:mp ids='MP_0005039'>hypoxia</z:mp> (i.e., hypoxic preconditioning; <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>) prior to transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (tMCAo) reduces <z:mpath ids='MPATH_124'>infarct</z:mpath> volume, blood-brain barrier disruption, and leukocyte migration </plain></SENT>
<SENT sid="1" pm="."><plain>CCL2 (<z:chebi fb="17" ids="50099">MCP</z:chebi>-1), typically regarded as a leukocyte-derived pro-inflammatory chemokine, can also be directly upregulated by <z:mp ids='MP_0005039'>hypoxia</z:mp>-induced transcription </plain></SENT>
<SENT sid="2" pm="."><plain>We hypothesized that such a <z:mp ids='MP_0005039'>hypoxia</z:mp>-induced upregulation of CCL2 is required for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>-induced ischemic tolerance </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: Adult male SW/ND4, CCL2-null, and <z:mp ids='MP_0002169'>wild-type</z:mp> mice were used in these studies </plain></SENT>
<SENT sid="4" pm="."><plain>Cortical CCL2/CCR2 message, protein, and cell-type specific immunoreactivity were determined following <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> (4 h, 8% O2) or room air control (21% O2) from 6 h through 2 weeks following <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Circulating leukocyte subsets were determined by multi-parameter flow cytometry in na√Øve mice and 12 h after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>CCL2-null and <z:mp ids='MP_0002169'>wild-type</z:mp> mice were exposed to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> 2 days prior to tMCAo, with immunoneutralization of CCL2 during <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> achieved by a monoclonal CCL2 antibody </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Cortical CCL2 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression peaked at 12 h after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> (both p &lt; 0.01), predominantly in cortical neurons, and returned to baseline by 2 days </plain></SENT>
<SENT sid="8" pm="."><plain>A delayed cerebral endothelial CCL2 message expression (p &lt; 0.05) occurred 2 days after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>The levels of circulating monocytes (p &lt; 0.0001), T lymphocytes (p &lt; 0.0001), and granulocytes were decreased 12 h after <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>, and those of B lymphocytes were increased (p &lt; 0.0001), but the magnitude of these respective changes did not differ between <z:mp ids='MP_0002169'>wild-type</z:mp> and CCL2-null mice </plain></SENT>
<SENT sid="10" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> did decrease the number of circulating CCR2+ monocytes (p &lt; 0.0001) in a CCL2-dependent manner, but immunohistochemical analyses at this 12 h timepoint indicated that this leukocyte subpopulation did not move into the <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> </plain></SENT>
<SENT sid="11" pm="."><plain>While <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volumes by 27% (p &lt; 0.01) in <z:mp ids='MP_0002169'>wild-type</z:mp> mice, CCL2-null mice subjected to tMCAo were not protected by <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Moreover, administration of a CCL2 immunoneutralizing antibody prior to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e> completely blocked (p &lt; 0.0001 vs. <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>-treated mice) the development of ischemic tolerance </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: The early expression of CCL2 in neurons, the delayed expression of CCL2 in cerebral endothelial cells, and CCL2-mediated actions on circulating CCR2+ monocytes, appear to be required to establish ischemic tolerance to focal <z:hpo ids='HP_0001297'>stroke</z:hpo> in response to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HPC</z:e>, and thus represent a novel role for this chemokine in endogenous neurovascular protection </plain></SENT>
</text></document>